Aliment Pharmacol Ther

• 

  Publication Venue For

  • Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome..  57:323-334. 2023
  • Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease. 2022
  • Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease-authors' reply..  56:1302-1303. 2022
  • Letter: efficacy of peppermint oil in irritable bowel syndrome-authors' reply..  56:1217-1218. 2022
  • Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up..  56:1264-1273. 2022
  • Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome. Authors' reply..  56:894-895. 2022
  • Impact of Rome IV irritable bowel syndrome on work and activities of daily living..  56:844-856. 2022
  • Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome..  56:932-941. 2022
  • Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom..  56:110-120. 2022
  • Editorial: estimating the costs of care in irritable bowel syndrome-a necessary step to enhance value-based care for a high-prevalence, low-cost condition. Authors' reply..  55:1590-1591. 2022
  • Editorial: risky business. What do sufferers' perceptions of risk from interventions for IBS really mean? Authors' reply..  55:1220-1221. 2022
  • Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome..  55:1311-1319. 2022
  • A novel phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for signal confirmation in early drug development..  55:1028-1037. 2022
  • Trends in statin utilisation in US adults with non-alcoholic fatty liver disease..  54:1481-1489. 2021
  • Systematic review with meta-analysis: association of Helicobacter pylori infection with gastro-oesophageal reflux and its complications..  54:988-998. 2021
  • Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease..  54:441-450. 2021
  • Editorial: recognising the efficacy of licensed drug therapies for irritable bowel syndrome on bloating-a step in the right direction for targeted treatment? Authors' reply..  54:198-199. 2021
  • Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation..  54:98-108. 2021
  • Editorial: co-morbid gastrointestinal conditions are an important consideration in IBS management-authors' reply..  53:1153-1154. 2021
  • Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value..  53:1126-1137. 2021
  • Systematic review with meta-analysis: risk factors for Barrett's oesophagus in individuals with gastro-oesophageal reflux symptoms..  53:968-976. 2021
  • Cross-linkage between bacterial taxonomy and gene functions: a study of metagenome-assembled genomes of gut microbiota in adult non-alcoholic fatty liver disease..  53:722-732. 2021
  • Editorial: will clusters for anxiety, depression, sleep disturbance and fatigue symptoms predict treatment outcomes in functional dyspepsia? Authors' reply..  53:652-653. 2021
  • Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms..  53:253-264. 2021
  • Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia..  53:8-21. 2021
  • Letter: faecal microbiota transplantation for irritable bowel syndrome-room for improvement..  52:923-924. 2020
  • Systematic review with meta-analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria..  52:762-773. 2020
  • Editorial: minesapride for irritable bowel syndrome with constipation..  52:713-714. 2020
  • Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis..  52:619-636. 2020
  • Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence..  51:1384-1396. 2020
  • Commentary: estimating the prevalence of IBS globally-past, present and future..  51:198-199. 2020
  • Editorial: blood biomarkers for advanced liver fibrosis in non-alcoholic fatty liver disease-not a simple choice?.  51:179-180. 2020
  • Editorial: understanding differences in patient response to ondansetron in irritable bowel syndrome with diarrhoea-are we any closer?.  50:825-826. 2019
  • Editorial: awareness and prevention of intravenous iron-induced hypophosphataemia..  50:609-610. 2019
  • Editorial: older patients are significantly more likely to have colon ischaemia-associated conditions that are chronic and complex..  50:329-330. 2019
  • Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome..  50:240-248. 2019
  • Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. Authors' reply..  49:1254-1255. 2019
  • Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial..  49:1205-1213. 2019
  • Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors..  49:1195-1204. 2019
  • Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome..  48:1044-1060. 2018
  • Editorial: frequency of surveillance and survival in hepatocellular carcinoma-authors' reply..  48:229-230. 2018
  • Editorial: measuring hypervigilance and anxiety in oesophageal disorders..  47:1559-1560. 2018
  • Editorial: platelet transfusions in cirrhosis-do the risks outweigh the unclear benefits?.  47:1553-1554. 2018
  • Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area..  47:1490-1501. 2018
  • Editorial: diabetes, obesity and clinical inertia-the recipe for advanced NASH. Authors' reply..  47:1221-1222. 2018
  • Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy..  47:1001-1011. 2018
  • Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis..  47:645-656. 2018
  • Genetic risk factors for perception of symptoms in GERD: an observational cohort study..  47:289-297. 2018
  • Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration..  47:268-278. 2018
  • Editorial: subgroups in irritable bowel syndrome-more than just diarrhoea and constipation?.  46:697. 2017
  • Editorial: probiotics in inflammatory bowel disease-wrong organisms, wrong disease, or flawed concepts? Authors' reply..  46:633-634. 2017
  • Letter: inconsistency in reporting of hypophosphatemia after intravenous iron..  46:641-643. 2017
  • Editorial: mesalazine to prevent recurrent acute diverticulitis-the final nail in the coffin..  46:461-462. 2017
  • Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease..  46:389-400. 2017
  • Editorial: latent class analysis to improve confidence in the diagnosis of IBS - authors' reply..  45:1268-1269. 2017
  • Letter: NICE referral criteria for lower gastrointestinal alarm features - not ideal but not poor either. Authors' reply..  45:1176. 2017
  • Derivation and validation of a diagnostic test for irritable bowel syndrome using latent class analysis..  45:824-832. 2017
  • Letter: causes of fatigue in inflammatory bowel disease remain uncertain..  45:762-763. 2017
  • Editorial: volatile organic compounds in irritable bowel syndrome - technology for an accurate and reliable point-of-care test?.  45:563-564. 2017
  • Non-alcoholic fatty liver diseases and risk of colorectal neoplasia..  45:345-353. 2017
  • Poor predictive value of lower gastrointestinal alarm features in the diagnosis of colorectal cancer in 1981 patients in secondary care..  45:91-99. 2017
  • The learning curve for interpretation of oesophageal high-resolution manometry: a prospective interventional cohort study..  45:291-299. 2017
  • The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel disease..  45:63-74. 2017
  • Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms..  44:1253-1264. 2016
  • Distal mean nocturnal baseline impedance on pH-impedance monitoring predicts reflux burden and symptomatic outcome in gastro-oesophageal reflux disease..  44:890-898. 2016
  • Editorial: challenging established perceptions of brain-gut interactions in functional gastrointestinal disorders - brain-gut, gut-brain, or both?.  44:899-900. 2016
  • Effects of disturbed sleep on gastrointestinal and somatic pain symptoms in irritable bowel syndrome..  44:246-258. 2016
  • Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis..  44:157-169. 2016
  • Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis..  44:117-126. 2016
  • Letter: biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease - authors' reply..  43:1246. 2016
  • Letter: deleterious effects of smoking on post-operative Crohn's disease - authors' reply..  43:1248. 2016
  • Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease..  43:549-561. 2016
  • Letter: smoking as a modifiable risk factor for a complicated course in Crohn's disease..  43:440. 2016
  • Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers..  43:356-363. 2016
  • Letter: therapeutic trial is more informative than SeHCAT to diagnose bile acid malabsorption--authors' reply..  42:781. 2015
  • Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers..  42:491-503. 2015
  • Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea..  42:3-11. 2015
  • Efficacy of hypnotherapy in one thousand patients with irritable bowel syndrome..  41:1222-1223. 2015
  • Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease..  41:1227-1236. 2015
  • Letter: irritable bowel syndrome is significantly associated with somatisation - authors' reply..  41:791-792. 2015
  • Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir..  41:671-685. 2015
  • Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating..  41:449-458. 2015
  • Editorial: the overlap of atopy and functional gastrointestinal disorders in primary care--authors' reply..  40:1244-1245. 2014
  • Increased prevalence of autoimmune diseases in functional gastrointestinal disorders: case-control study of 23471 primary care patients..  40:827-834. 2014
  • The overlap of atopy and functional gastrointestinal disorders among 23,471 patients in primary care..  40:382-391. 2014
  • Letter: bile acid diarrhoea is not a rare cause of diarrhoea in secondary care..  40:216. 2014
  • Letter: is there a bi-directional relationship between depression and IBD?.  40:213. 2014
  • Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease..  40:3-15. 2014
  • Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease..  39:447-458. 2014
  • Characteristics of functional bowel disorder patients: a cross-sectional survey using the Rome III criteria..  39:312-321. 2014
  • Letter: effects of iron therapy after non-variceal acute upper gastrointestinal bleeding..  39:346. 2014
  • Commentary: the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument..  37:750. 2013
  • The natural history of gastro-oesophageal reflux symptoms in the community and its effects on survival: a longitudinal 10-year follow-up study..  37:323-331. 2013
  • NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people..  37:195-203. 2013
  • Letter: the effects of overlapping symptoms on the response to PPI therapy in GERD..  36:207. 2012
  • Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: a large single-centre experience..  35:284-291. 2012
  • Is otilonium bromide globally effective in irritable bowel syndrome?.  34:1034-1035. 2011
  • Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience..  34:405-407. 2011
  • Meta-analysis: Coeliac disease and hypertransaminasaemia..  34:33-40. 2011
  • Meta-analysis: the epidemiology of noncardiac chest pain in the community..  34:172-180. 2011
  • Do dried plums really help constipation?.  33:1258-1259. 2011
  • Systematic review: the effects of fibre in the management of chronic idiopathic constipation..  33:895-901. 2011
  • Defining a responder in treatment trials for chronic idiopathic constipation..  33:285-286. 2011
  • A UK-based cost-utility analysis of radiofrequency ablation or oesophagectomy for the management of high-grade dysplasia in Barrett's oesophagus..  32:1332-1342. 2010
  • Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience..  32:1357-1363. 2010
  • Effect of oral zinc in hepatic encephalopathy remains unclear..  32:1405-1406. 2010
  • Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis..  32:1297-1306. 2010
  • Infliximab rescue therapy in ulcerative colitis, and the effect on subsequent colectomy rates..  32:1294-1295. 2010
  • Reporting of relapse rates in a trial of mesalazine for ulcerative colitis..  32:1205-1206. 2010
  • Modulation of salivation and heartburn in response to the site of acid infusion in the human oesophagus..  32:795-800. 2010
  • Dyspepsia and irritable bowel syndrome: mutually exclusive conditions?.  32:612-613. 2010
  • Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome..  32:144-158. 2010
  • Renzapride in IBS: is efficacy in the eye of the beholder?.  32:113-114. 2010
  • Systematic review: prognostic tests of paracetamol-induced acute liver failure..  31:1064-1076. 2010
  • Alverine citrate, simeticone, and Rome III irritable bowel syndrome..  31:767-768. 2010
  • Probiotics in irritable bowel syndrome: underachievers or underpowered?.  31:922-923. 2010
  • Applicability of the reported prevalence of bile salt malabsorption in irritable bowel..  31:161-162. 2010
  • Generalized anxiety disorder and irritable bowel syndrome..  30:1087-1088. 2009
  • 10-biomarker algorithm to identify irritable bowel syndrome..  30:95-96. 2009
  • Meta-analysis: yield of diagnostic tests for coeliac disease in dyspepsia..  30:28-36. 2009
  • Fluctuation of gastrointestinal symptoms in the community: a 10-year longitudinal follow-up study..  28:1013-1020. 2008
  • Meta-analysis: Helicobacter pylori'test and treat' compared with empirical acid suppression for managing dyspepsia..  28:534-544. 2008
  • Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C..  27:422-432. 2008